Navigation Links
ThromboGenics N.V.: Business Update
Date:11/6/2008

LEUVEN, Belgium, November 6 /PRNewswire-FirstCall/ -- ThromboGenics NV (Euronext Brussels: THR), a biotechnology company focused on innovative treatments for eye disease, vascular disease and cancer, is today issuing a business update for the nine months period ended 30 September 2008.

Patrik De Haes, CEO of ThromboGenics, commenting on today's announcement, said: "ThromboGenics' clinical development programs continue to progress as anticipated. We are now working hard to prepare for the Phase III clinical program for microplasmin in eye disease following a successful End of Phase II Meeting with the FDA. The recent positive results from our Phase II trials with microplasmin have given us further confidence that this product has the potential to make a real difference in the field of eye disease. We are also developing a good working relationship with our strategic partner Roche as the clinical development of our new anti-cancer antibody TB-403 continues to progress. With our solid financial situation, I believe that ThromboGenics will deliver further important corporate milestones over the next 12 to 18 months as we continue to work to build value for our shareholders."
Financial Update

- In the first nine months of 2008, ThromboGenics achieved

revenues of EUR 30.3 million, mainly from out-licensing activities.

Operating expenses were EUR 17.0 million during this nine month period,

the majority of which were due to R&D expenses related to an increasing

number of clinical development programs.

- As of 30 September 2008, ThromboGenics had EUR 60.9 million

in cash and cash equivalents. This compares to EUR 50.6 million on 30

September 2007 and EUR 40.1 million on 31 December 2007. ThromboGenics

believes that this level of funding will allow it to complete the Phase

III program for the initial indication for microplasmin in eye disease.

- In late July, ThromboG
'/>"/>

SOURCE ThromboGenics NV
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. ThromboGenics Announces Half Year Results 2008
2. ThromboGenics Appoints Dr. Patrik De Haes as Chief Executive Officer
3. ThromboGenics Announces Private Investors Acquire 8% Stake in the Company
4. ThromboGenics and BioInvent Announce a Strategic Alliance With Roche for TB-403, a Novel Anti-Cancer Antibody
5. ThromboGenics N.V. - Business Update
6. ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke
7. ThromboGenics Announces 2007 Full Year Results
8. ThromboGenics and BioInvent Receive Approval to Begin Clinical Trials of TB-403 for the Treatment of Cancer
9. ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting
10. ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annual Meeting
11. ThromboGenics and BioInvent Announce Publication of Exciting Data on a Novel Class of Angiogenesis Inhibitors in Cell
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... 22, 2014 Nuvilex, Inc. (OTCQB: NVLX) – ... people worldwide are living with diabetes, with  that number ... The global market for diabetes treatments is approximately $500 ... worldwide died from pancreatic cancer.  Pancreatic cancer is the ... in the United States , and ...
(Date:10/20/2014)... YORK , Oct. 20, 2014 ... their experimental ZMapp™ antibody therapeutic to fight the ... how difficult and time-consuming the production of pharmaceuticals ... market research publisher said that while some may ... of this compound, those with industry knowledge are ...
(Date:10/20/2014)... 20, 2014 , A major ... and the delivery of care has revealed changing trends ... inequalities in the provision of healthcare services across the ... by United European Gastroenterology (UEG), have been announced today ... awareness of the burden of GI disorders across ...
(Date:10/20/2014)... 2014 Earle Martin , ... today that Ellen Teplitzky, an experienced attorney specializing ... pharmaceutical industry, has joined the firm as Director ... services practice. NDA Partners provides legal services, ... testimony, to top law firms and their clients ...
Breaking Biology Technology:Nuvilex Brief Analyst Report: Thinking Outside the Box by BrokerBank Securities, Inc. 2Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 2Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 3Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 2Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 3Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 4Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 5NDA Partners Appoints Ellen Teplitzky, JD as Director of its Legal Services Practice 2
... March 14 GHI Medical, a national,leader in ... to,correlate the results of a current test used ... is called the TrichoBioScan(TM)., The TrichoBioScan(TM) consists ... with an in-depth microscopic analysis of a person,s,hair ...
... 14 ,Renovis, Inc. (Nasdaq: RNVS ), a biopharmaceutical ... major medical needs in the areas of,neurological and inflammatory ... year ended December 31, 2007., Revenue for the ... was,$1.3 million and $9.8 million, respectively, compared to $2.2 ...
... Diagnostics,Incorporated (NYSE: DGX ), the nation,s leading ... it is scheduled to speak,at the Lehman Brothers ... 2008, at The Loews Miami Beach Hotel, Miami, ... at 9:00 a.m.,Eastern Time., The presentation will ...
Cached Biology Technology:Renovis Reports Fourth Quarter and Full Year 2007 Financial Results 2Renovis Reports Fourth Quarter and Full Year 2007 Financial Results 3Renovis Reports Fourth Quarter and Full Year 2007 Financial Results 4Renovis Reports Fourth Quarter and Full Year 2007 Financial Results 5Renovis Reports Fourth Quarter and Full Year 2007 Financial Results 6Renovis Reports Fourth Quarter and Full Year 2007 Financial Results 7Quest Diagnostics to Speak at Lehman Brothers 11th Annual Global Healthcare Conference 2
(Date:10/15/2014)... University Mainz (JGU) as a full member, ensuring ... a significant nationwide standing in the field of ... Gutenberg University Mainz as a full member of ... and international competition for the best minds and ... proud that Mainz University has been recognized as ...
(Date:10/15/2014)... Fred Alt will be awarded the 44th Rosenstiel Award ... for his pioneering research exploring the mechanisms of genomic ... cancer cells. Alt is the second alumnus to win ... Nobel Prize in 2003. , Alt is the Charles ... at Harvard Medical School and an investigator at the ...
(Date:10/14/2014)... 2014)—It,s been millions of years since T. rex ... by Ohio University scientists is breathing life back into ... dinosaur snouts. The research has important implications for how ... to enhance the sense of smell and cool their ... Ohio University doctoral student Jason Bourke, lead author of ...
Breaking Biology News(10 mins):Johannes Gutenberg University Mainz joins Germany's Gauss-Allianz as a full member 2Johannes Gutenberg University Mainz joins Germany's Gauss-Allianz as a full member 3Brandeis awards 44th Rosenstiel Award to pioneering geneticist Fred Alt 2Dinosaur breathing study shows that noses enhanced smelling and cooled brain 2Dinosaur breathing study shows that noses enhanced smelling and cooled brain 3
... Lysmata amboinensis usually live in monogamous pairs, but dark ... Central,s open access journal Frontiers in Zoology shows ... attack and kill each other until only a single pair ... This means that they start out as males but, as ...
... pollination, the number of seeds they produce, or their relative ... of pollen. The number of visits a plant may receive ... plant density. But what if a plant happens to grow ... pollinators visiting its flowers? Will all the effort put into ...
... and depth of the Deepwater Horizon oil spill ... severity of ecological damage and to develop restoration plans for ... report by the National Research Council. A broad approach ... production -- in addition to replacing natural resources damaged by ...
Cached Biology News:Violent passions jealous cleaner shrimp murder their rivals 2How does a plant survive with few mates or pollinators? A European herb has figured out its own way 2How does a plant survive with few mates or pollinators? A European herb has figured out its own way 3New report offers broad approach to assessing impacts of ecological damage 2New report offers broad approach to assessing impacts of ecological damage 3
BD BioCoat Collagen IV 35 mm Culture Dishes, tissue-culture treated polystyrene with a uniform application of mouse collagen type IV....
... are designed for sequencing inserts cloned into ... or T3 RNA polymerase promoters, or lambda ... at a concentration of 0.1 µg/µl in ... DNA sequencing reactions using SequiTherm™ EXCEL™ II ...
BD BioCoat Matrigel Matrix 35 mm Culture Dishes Coating : BD MatrigelTM Basement Membrane Matrix ,Surface : ECM/attachment factors ,Surface area : 9.6 cm2 ,Dim nominal : 35 mm x 10 mm ,Vo...
BD BioCoat Collagen I 35 mm Culture Dishes, tissue-culture treated polystyrene with a uniform application of rat tail collagen type I....
Biology Products: